Article
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial.
The Lancet. Respiratory medicine - 1 Feb 2026
Zhong Jia, Zhao Jun, Duan Jianchun, Fang Jian, Fei Kailun, Li Xiaoyan, Chen Jiayan, Wang Zhijie, Chu Qian, Yu Yan, Liu Zhe, Zhang Li, Zhao Yanqiu, Li Xingya, Wu Lin, Xing Ligang, Zhuang Wu, Fang Xuefeng, Chang Jianhua, Pan Yueyin, Dong Xiaorong, Liu Lian, Bai Chunmei, Pan Pinhua, Song Qibin, Jin Bo, Cao Baoshan, Ye Feng, Shi Jianhua, Tang Kejing, Wang-Gillam Andrea, Ding Yuli, Bi Chao, Shao Yang, Pang Jiaohui, Wan Rui, Sun Boyang, Xu Jiachen, Wang Jie
Abstract excerpt
BACKGROUND: Monotherapy with KRASG12C (ie, KRAS Gly12Cys) inhibitors has emerged as a mainstream treatment for patients with KRASG12C -mutated non-small-cell lung cancer (NSCLC). Synergistic effects have been observed with the combination of a KRASG12C inhibitor and a SHP2 inhibitor in multiple xenograft models. We aimed to evaluate the safety and efficacy of the KRASG12C inhibitor glecirasib combined with the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.